Results from a first-in-human phase 1 study of savolitinib in 48 patients with locally advanced or metastatic solid tumours was published in Clinical Cancer Research last month.
Savolitinib is a selective MET inhibitor. In the study, the maximum tolerated dose was found to be 800 mg daily, and the recommended dose for phase 2 testing is 600 mg a day. Savolitinib was tolerable, and the most frequently reported adverse events were nausea (63%), vomiting (42%), fatigue (42%), and peripheral oedema (31%). Durable partial responses were seen in 3 patients with papillary renal cell carcinoma (pRCC). These patients also had mutations in their MET genes.
The researchers concluded that savolitinib was tolerable, and the phase 2 dose was established as 600 mg daily. Further study of the anti-tumour activity of savolitinib is needed in patients with pRCC.